Baclofen
Brand names: Baclofen, Lioresal Intrathecal, Fleqsuvy, Gablofen, Lyvispah
At a glance
- Medicare prescriptions, 2024
- 4,411,252
- Medicare drug cost
- $75.2M
- Average cost per prescription
- $17.06
- Clinicians who prescribed it
- 107,833
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
LYVISPAH is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. LYVISPAH may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
From the FDA-approved prescribing information (label dated April 2023). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 24.5%
- Nurse Practitioners 20.3%
- Internal Medicine 19.3%
- Physician Assistants 8.1%
- Neurology 7.3%
- Pain Medicine 6.0%
- Physical Medicine & Rehabilitation (PM&R) 3.6%
- General Practice 3.0%
- Geriatric Medicine 1.7%
- Rheumatology 1.2%
- Anesthesiology 0.7%
- Hospitalist 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 8% from 2019 to 2024.
Biggest change by state since 2019
- Montana +26%
- Connecticut +23%
- Idaho +22%
- Nebraska +22%
- Wyoming +21%
- Maine (smallest change) −3%
- Tennessee (smallest change) −3%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amneal Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | white freeform granule | |
| 10 mg | white freeform granule | |
| 20 mg | white freeform granule | |
Anvi Pharmaceuticals Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white freeform granule | |
Marlex Pharmaceuticals Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white round tablet, 9 mm, scored to split in 2 | LCI 1330 |
| 20 mg | white round tablet, 10 mm, scored to split in 2 | LCI 1337 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 9 mm, scored to split in 2 | 025 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $83,374 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Piramal Critical Care $82,108
- Metacel Pharmaceuticals LLC $1,266
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Nov 2025 · Golden State Medical Supply Inc. · Class II
Presence of Foreign Tablets/Capsules
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.